



โรงพยาบาลกรุงเทพ
BANGKOK HOSPITAL

Wattanosoth Tumor Registry

09



Wattanosoth Tumor Registry

2009



Painting created by 55 year old lovely female patient who had 2 different cancers and received treatments at Wattanosoth Hospital. She passed away in peace after 5 years fighting with those cancers. Daughter said being with cancer brought back warmth, mother-daughter relationship and thought her mother life seemed happier and joyful than before cancer came.

TUMOR REGISTRY TEAM (September, 2010)

- | | |
|-----------------------------------|---------------------|
| 1. Surachai Sitawarin, M.D. | Chairman |
| 2. Komgrit Tanisaro, M.D. | Vice Chairman |
| 3. Saengduan Chindavijak, M.D. | Committee Member |
| 4. Natthaphum Khanchanaporn, M.D. | Committee Member |
| 5. Pichet Pariyarungri | Committee Member |
| 6. Panissara Onlamoon | Secretary |
| 7. Waraphorn Chomphu | Secretary Assistant |

Table of Contents

Message from CEO	2
Tumor Registry 2009 : Abstract	4
Annual Tumor Registry 2009	5
Distribution by Age & Sex, The 10 Leading Site of Cancer, Method of Diagnosis, Patient Category, Staging, Type of Primary Treatment, Patient Follow up, Patient Nationality	
Review of Breast Cancer	14
Review of Colorectal Cancer	19
Review of Lung Cancer	24
Review of Hepatobiliary Cancer	30
Review of Prostate Gland Cancer	36
Hematologic Malignancies 2009	41
Age Distribution in All Male Cancer Number of Case	52
Age Distribution in All Female Cancer Number of Case	54
Hematologic Malignancies 2009 : Executive Summary	56
Activity	57
Highlighted Technology	59

Message from CEO

In line with the mission of Bangkok Hospital Medical Center in delivering the highest quality medical care service that is of an internationally accepted standard, Wattanosoth Hospital is committed in making a very significant difference in the provision of medical care for “cancer patients” both in prevention in the earliest stage and providing the most competent medical care by the high caliber team.

I am most delighted to welcome all of you to “**Wattanosoth Tumor Registry 2009.**” The annual report wisely presents an overview of experiences, practices, qualified cancer patient analyses, and the previous and current statistical data of all types of the reportable cancers carried out by the professional team of Wattanosoth Hospital. Additionally, the report and statistics of the Tumor Registry 2009 also include the data in Hematology, which is the latest service at Wattanosoth Hospital. I am proud to inform you that Wattanosoth Hospital has recently set up a Bangkok Hematology Center with the aim of strengthening the competency of medical care service to our cancer patients. The center headed by renowned cancer physicians providing comprehensive medical care through multidisciplinary teams of highly trained hematology specialists. The Tumor Registry 2009 also indicates the trend of the major diseases like cancer in the future. I trust the Tumor Registry 2009 will certainly enable us to bring valuable benefits to both the medical profession and the patients we serve.

In this connection, I wish to extend my heartfelt gratitude and appreciation to Wattanosoth Hospital Team and to everyone who has contributed to this accomplishment.



(Chatree Duangnet, M.D. FAAP, FACMQ)
Hospital Director, Wattanosoth Hospital
Chief Executive Officer, Bangkok Hospital Medical Center
Bangkok Dusit Medical Services Plc.

September, 2010



Tumor Registry 2009 : Abstract

Total new cases diagnosed malignancy at Bangkok Hospital Medical Center is 1,395 cases (excluding the hematologic malignancy and brain tumor). There was 8.4 percent increasing in total number as compared to 1,277 cases in year 2008. Sex ratio is 1:1 an age distribution is not changed as compared to year 2008. Patient who are between 45-69 YO are majority and accounted more than half of overall.

Patient age group of 60-64 YO is accounted for almost 15 percent. Anyway, average age in male patients is slightly younger.

Top 5 malignancies are followings ; 1) Breast (18.64 percent) 2) Colorectal (12.11 percent) 3) Lung (11.47 percent) 4) Hepatobiliary (7.31 percent) and 5) Prostate gland (6.52 percent). The top 5 trend is not different from in 4 year (2006-2009) collection (Breast, Colorectal, Lung, Liver and Prostate). Anyway, when compared to last year, overall number of cases in Liver was dropped significantly 15.7 percent. Contrast to Breast cancer, Colorectal cancer, Lung cancer and Prostate cancer which still rising in number 13 percent, 16 percent, 6.9 percent and 9.9 percent respectively. Lung cancer is still leading cancer in male for 4 year and still constant this year.

Carcinoma of the cervix is the third cancer female in BMC but number 7th in both sexes and stepping up 19.2 percent compared to year 2008. Urinary bladder, Head & Neck and Renal pelvis are stepping up and ranking at 6th, 9th, 10th this year.

Considering patients who received treatment at BMC, Stage I is 28 percent, Stage II is 19 percent, Stage III is 18 percent and Stage IV is 25 percent. Unknown stage (due to lack of pertinent information) trend low is 5 percent compared to 11.5 percent last year.

Considering the primary treatments that have been done in BMC, Surgery is still the majority (30 percent) followed by Radiation therapy (10 percent) and Chemotherapy (5 percent). Chemotherapy and Targeted therapy show same trend is 6 percent. Intervention treatment is down from 4 to 2 percent.

Patient who were diagnosed cancer at BMC tend to decide receiving treatment at BMC 30 percent (34.5 percent last year) and these patients decide to having primary treatment in other hospitals 13 percent (13 percent last year). Surprisingly, even patients who come from other hospitals are seeking second opinion at BMC only is significantly increased (more than one-fourth of all) but those who come and continue treatment at BMC is lower than last year (15 percent dropped to 13 percent)


Patient who are still alive after diagnosing or treatment cancer in 2009 is 42 percent, alive without disease is 11 percent. Patient was dead with cancer as leading cause is 3 percent. Rate of lost to follow up is decrease 3 to 1 percent.

Ratio of Thai : non-Thai patient is 3:2 compared to 3:2 in year 2008. This ratio is equally. The top 5 rankings are UAE, Myanmar, Bangladesh, Oman & Gatar and British respectively.

WSH. ANNUAL CANCER REGISTRY 2009

DISTRIBUTION OF ALL CANCER BY AGE & SEX

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	3	0.43	0	0.00	3	0.22
05 - 09	1	0.14	2	0.29	3	0.22
10 - 14	3	0.43	2	0.29	5	0.36
15 - 19	1	0.14	1	0.14	2	0.14
20 - 24	5	0.71	5	0.72	10	0.72
25 - 29	7	0.99	8	1.16	15	1.08
30 - 34	13	1.84	25	3.62	38	2.72
35 - 39	17	2.41	42	6.09	59	4.23
40 - 44	34	4.82	77	11.16	111	7.96
45 - 49	48	6.81	95	13.77	143	10.25
50 - 54	71	10.07	79	11.45	150	10.75
55 - 59	92	13.05	92	13.33	184	13.19
60 - 64	119	16.88	79	11.45	198	14.19
65 - 69	85	12.06	64	9.28	149	10.68
70 - 74	90	12.77	35	5.07	125	8.96
75 - 79	59	8.37	39	5.65	98	7.03
80 - 84	42	5.96	25	3.62	67	4.80
85 - 89	11	1.56	13	1.88	24	1.72
90 - 94	2	0.28	4	0.58	6	0.43
95+	2	0.28	3	0.43	5	0.36
Total	705	100.00	690	100.00	1,395	100.00




OVERALL CANCER


THE 10 LEADING SITE OF CANCER IN BMC 2009

Code	Primary site	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
C50	Breast	0	0.00	260	37.68	260	18.64
C18-C20	Colorectal	104	14.75	65	9.42	169	12.11
C33-C34	Lung	119	16.88	41	5.94	160	11.47
C22-C24	Liver & Hepatobiliary	74	10.50	28	4.06	102	7.31
C61	Prostate gland	91	12.91	0	0.00	91	6.52
C67	Urinary bladder	45	6.38	9	1.30	54	3.87
C53	Cervix	0	0.00	52	7.54	52	3.73
C73	Thyroid gland	19	2.70	32	4.64	51	3.66
C11-C14	Head & Neck	32	4.54	17	2.46	49	3.51
C64-C65	Renal pelvic	26	3.69	15	2.17	41	2.94


THE -10 OF CANCER ALL GENDER IN BMC 2009




THE -10 OF CANCER IN MALE 2009



THE -10 OF CANCER IN FEMALE 2009




METHOD OF DIAGNOSIS (BOTH SEX)




** Other = Previously diagnosed as Cancer from other Hospital but no document of Pathology

PATIENT CATEGORY OF ALL CANCER IN BMC



** Dx = Diagnosis for Cancer (Dx by Pathology, Cytology or Imaging)
 Rx = Treatment
 Here = Within Bangkok Hospital Medical Center
 Other = Outside Bangkok Hospital Medical Center


STAGING (BOTH SEX)




** Non stage = Carcinoma in situ and in case of CA Brain

Unspecified stage = Incomplete staging due to Patient information is not enough


Male



Female




STAGING (TREATMENT IN BMC)




** Non stage = Carcinoma in situ and in case of CA Brain

Unspecified stage = Incomplete staging due to Patient information is not enough

Male




Female




MANAGEMENT OF PRIMARY TREATMENT

Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	179	25.39	232	33.62	411	29.46
Radiation+Brachytherapy	68	9.65	66	9.57	134	9.61
Targeted therapy	5	0.71	0	0.00	5	0.36
Nuclear medicine	2	0.28	8	1.16	10	0.72
Chemotherapy	29	4.11	39	5.65	68	4.87
Palliative care only	13	1.84	20	3.04	33	2.37
Immunotherapy	1	0.14	0	0.00	1	0.07
Hormonal therapy	8	1.13	6	0.87	14	1.00
Intervention	21	2.98	5	0.72	26	1.86
Concurrent chemoradiation	22	3.12	23	3.33	45	3.23
Investigation	113	16.03	87	12.61	200	14.34
2 nd Opinion	112	15.89	108	15.65	220	15.77
Supportive	3	0.43	3	0.29	6	0.43
Follow up	2	0.28	15	2.17	17	1.22
PET/CT	100	14.18	58	8.41	158	11.33
Bone scan	27	3.83	20	2.90	47	3.37
Total	705	100.00	690	100.00	1,395	100.00

TYPE OF PRIMARY TREATMENT (BOTH SEX)



PATIENT FOLLOW UP



** AWD = *Alive with disease*

AOD = *Alive without disease*


DWD = *Dead with disease*

DOD = *Dead other disease*

Loss Follow up = *Not attended*

No Follow up = *Intend not to continue diagnosis or treatment at BMC*

REFERRING HOSPITAL



BGH (การส่งต่อมายังในศูนย์การแพทย์ sw.กรุงเทพฯ)
 BPH (กรุงเทพฯ พญา)
 BRH (กรุงเทพฯ รอยง)
 BCH (กรุงเทพฯ ดันบุรี)

SVH (สภิติอว สุมวิท)
 BHH (กรุงเทพฯ ทาไทร)
 SNH (สภิติอว ศรีนครินทร์)
 BSH (กรุงเทพฯ สุม)


BNH (บางกอกเนอสซิ่งโฮ)
 BKN (กรุงเทพฯ นครราชสีมา)
 BPK (กรุงเทพฯ ภูเก็ต)
 SSH (สภิติอว ศรีราชา)

PATIENT NATIONALITY

TOTAL NATIONALITY



FOREIGN NATIONALITY




BREAST CANCER PATHOLOGY ACCORDING OF BREAST CANCER

Tumor site		Number
C50.0	Nipple	6
C50.1	Central portion of breast	2
C50.2	Upper-inner quadrant of breast	16
C50.3	Lower-inner quadrant of breast	11
C50.4	Upper-outer quadrant of breast	75
C50.5	Lower-outer quadrant of breast	20
C50.6	Axillary tail of breast	0
C50.8	Overlapping lesion of breast	3
C50.9	Breast, NOS	127
Total		260

Pathology Report		Number
M8000/3	Malignant neoplasm	72
M8500/3	Invasive ductal carcinoma	177
M8510/3	Medullary carcinoma	2
M8520/3	Lobular carcinoma	7
M8540/3	Paget disease, mammary	1
M8543/3	Paget disease and intraductal carcinoma of breast	1
Total		260

AGE




METHOD OF DIAGNOSIS (TREATMENT IN BMC)

Method of diagnosis	Number	Percent
Biochemical	0	0.00
Other	10	6.80
Cytology	3	2.04
Histology	134	91.16
Imaging	0	0.00
Total	147	100.00

** Other = Previously diagnosed as Breast cancer from other Hospital but no document of Pathology

STAGING (TREATMENT IN BMC)



** Unspecified stage = Cannot staging in Breast cancer due to Patient information is not enough

TYPE OF TREATMENT (IN BMC ONLY)

Type of treatment	Female	
	Number	Percent
SUR. only	30	20.41
RT only	22	14.97
CT only	4	2.72
H only	3	2.04
Palliative care only	3	2.04
SUR.+RT	5	3.40
SUR.+CT	26	17.69
SUR.+H	15	10.20
CT+H	1	0.68
CT+T	2	1.36
RT+H	7	4.76
RT+CT	5	3.40
SUR.+RT+CT	12	8.16
SUR.+RT+H	2	1.36
SUR.+CT+H	3	2.04
SUR.+CT+T	2	1.36
RT+CT+T	1	0.68
RT+CT+H	1	0.68
SUR.+RT+T	1	0.68
SUR.+RT+CT+H	1	0.68
SUR.+RT+CT+T	1	0.68
Total	147	100.00

** SUR. = Surgery

RT = Radiation therapy

CT = Chemotherapy


T = Targeted therapy

H (Hormone) = Hormonal therapy

Im. = Immunotherapy

2nd Opinion = Consult only (No treatment)

FOLLOW UP STATUS



** AWD = Alive with disease

AOD = Alive without disease

DWD = Dead with disease

Loss Follow up = Not attended

No Follow up = Intend not to continue diagnosis or treatment at BMC


COLORECTAL CANCER PATHOLOGY ACCORDING OF COLORECTAL CANCER

Tumor site		Number
C18.0	Cecum colon	7
C18.1	Appendix	0
C18.2	Ascending colon	8
C18.3	Hepatic flexure of colon	4
C18.4	Transverse colon	6
C18.5	Splenic flexure of colon	5
C18.6	Descending colon	10
C18.7	Sigmoid colon	39
C18.9	Colon, NOS	33
C19.9	Rectosigmoid colon	15
C20.9	Rectum	42
Total		169

Pathology Report		Number
M8000/3	Malignant neoplasm	43
M8140/3	Adenocarcinoma	119
M8246/3	Neuroendocrine carcinoma	1
M8480/3	Mucinous adenocarcinoma	4
M8481/3	Mucin producing adenocarcinoma	2
Total		169

COLORECTAL CANCER

AGE & SEX




METHOD OF DIAGNOSIS (TREATMENT IN BMC)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Biochemical	0	0.00	0	0.00	0	0.00
Other	3	7.69	2	6.25	5	7.04
Cytology	0	0.00	0	0.00	0	0.00
Histology	36	92.31	30	93.75	66	92.96
Imaging	0	0.00	0	0.00	0	0.00
Total	39	100.00	32	100.00	71	100.00

** Other = Previously diagnosed as Colorectal cancer from other Hospital but no document of Pathology

STAGING (TREATMENT IN BMC)




TYPE OF TREATMENT (IN BMC ONLY)

Type of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR. only	17	43.59	9	28.13	26	36.62
RT only	1	2.56	0	0.00	1	1.41
CT only	8	20.51	4	12.50	12	16.90
Concurrent CT-RT	0	0.00	2	6.25	2	2.82
Palliative care only	2	5.13	4	12.50	6	8.45
SUR.+RT	1	2.56	0	0.00	1	1.41
SUR.+CT	8	20.51	9	28.13	17	23.94
CT+T	1	2.56	1	3.13	2	2.82
SUR.+RT+CT	0	0.00	1	3.13	1	1.41
SUR.+CT+T	1	2.56	2	6.25	3	4.23
Total	39	100.00	32	100.00	71	100.00

** SUR. = Surgery
 RT = Radiation therapy
 CT = Chemotherapy
 T = Targeted therapy

FOLLOW UP STATUS



** AWD = *Alive with disease*
 AOD = *Alive without disease*
 DWD = *Dead with disease*
 DOD = *Dead other disease*
 No Follow up = *Intend not to continue diagnosis or treatment at BMC*


LUNG CANCER PATHOLOGY ACCORDING OF LUNG CANCER

Tumor site		Number
C34.0	Main bronchus	1
C34.1	Upper lobe, lung	53
C34.2	Middle lobe, lung	5
C34.3	Lower lobe, lung	39
C34.8	Overlapping lesion of lung	0
C34.9	Lung, NOS	62
Total		160

Pathology Report		Number
M8000/3	Malignant neoplasm	32
M8010/3	Carcinoma, NOS	3
M8012/3	Large cell carcinoma, NOS	1
M8020/3	Carcinoma undifferentiated, NOS	5
M8021/3	Carcinoma anaplastic, NOS	4
M8031/3	Giant cell carcinoma	1
M8033/3	Pseudosarcomatous carcinoma	1
M8041/3	Small cell carcinoma, NOS	6
M8045/3	Combined small cell carcinoma	2
M8046/3	Non small cell carcinoma	29
M8070/3	Squamous cell carcinoma, NOS	8
M8140/3	Adenocarcinoma, NOS	47

Pathology Report		Number
M8240/3	Carcinoid tumor, NOS	2
M8246/3	Neuroendocrine carcinoma, NOS	2
M8250/3	Bronchiolo-aveolar adenocarcinoma, NOS	12
M8252/3	Bronchiolo-aveolar carcinoma, non mucinous	1
M8253/3	Bronchiolo-alveolar carcinoma, mucinous	1
M8260/3	Papillary adenocarcinoma, NOS	1
M8480/3	Mucinous adenocarcinoma	1
M8560/3	Adenosquamous carcinoma	1
Total		160

AGE & SEX




METHOD OF DIAGNOSIS (TREATMENT IN BMC)

Type of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Biochemical	0	0.00	0	0.00	0	0.00
Other	0	0.00	1	5.56	1	1.25
Cytology	8	12.90	1	5.56	9	11.25
Histology	50	80.65	16	88.89	66	82.50
Imaging	4	6.45	0	0.00	4	5.00
Total	62	100.00	18	100.00	80	100.00

** Other = Previously diagnosed as Lung cancer from other Hospital but no document of Pathology

STAGING (TREATMENT IN BMC)



** Unspecified stage = Cannot staging in Lung cancer due to patient information is not enough

TYPE OF TREATMENT (IN BMC ONLY)

Type of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR. only	6	9.68	5	27.78	11	13.75
RT only	18	29.03	5	27.78	23	28.75
CT only	4	6.45	3	16.67	7	8.75
Targeted therapy	3	4.84	0	0.00	3	3.75
Palliative care only	3	4.84	1	5.56	4	5.00
Concurrent CT-RT	7	11.29	1	5.56	8	10.00
SUR.+RT	2	3.23	0	0.00	2	2.50
SUR.+CT	4	6.45	1	5.56	5	6.25
CT+T	4	6.45	1	5.56	5	6.25
RT+T	2	3.23	1	5.56	3	3.75
RT+CT	3	4.84	0	0.00	3	3.75
SUR.+RT+CT	1	1.61	0	0.00	1	1.25
RT+CT+T	2	3.23	0	0.00	2	2.50
SUR.+RT+T	2	3.23	0	0.00	2	2.50
Concurrent CT-RT+I	1	1.61	0	0.00	1	1.25
Total	62	100.00	18	100.00	80	100.00

** SUR. = Surgery


RT = Radiation therapy

CT = Chemotherapy

T = Targeted therapy

I = Intervention

FOLLOW UP STATUS




** AWD = *Alive with disease*
AOD = *Alive without disease*
DWD = *Dead with disease*
DOD = *Dead other disease*
No Follow up = *Intend not to continue diagnosis or treatment at BMC*

HEPATOBIILIARY CANCER PATHOLOGY ACCORDING OF HEPATOBIILIARY CANCER


Tumor site		Number
C22.0	Liver	73
C22.1	Liver (Pathology is M8160/3)	14
C23.9	Gall bladder	11
C24.0	Extrahepatic bile duct	0
C24.1	Ampullar of vater	4
Total		102

Pathology Report		Number
M8000/3	Malignant neoplasm	37
M8140/3	Adenocarcinoma, NOS	9
M8160/3	Cholangiocarcinoma	10
M8170/3	Hepatocellular carcinoma, NOS	38
M8246/3	Neuroendocrine carcinoma, NOS	1
M8260/3	Papillary adenocarcinoma	1
M8480/3	Mucinous adenocarcinoma	3
M8481/3	Mucin producing adenocarcinoma	2
M8490/3	Signet ring cell adenocarcinoma	1
Total		102

PATHOLOGY REPORT OF HEPATOBIILIARY CANCER





AGE & SEX





Male Female

METHOD OF DIAGNOSIS (TREATMENT IN BMC)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Biochemical	11	26.83	2	14.29	13	23.64
Other	0	0.00	0	0.00	0	0.00
Cytology	0	0.00	0	0.00	0	0.00
Histology	16	39.02	9	64.29	25	45.45
Imaging	14	34.15	3	21.43	17	30.91
Total	41	100.00	14	100.00	55	100.00



STAGING (TREATMENT IN BMC)



** Unspecified stage = Incomplete staging due to Patient information is not enough

TYPE OF TREATMENT (IN BMC ONLY)

Type of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR. only	12	29.27	3	21.43	15	27.27
RT only	2	4.88	0	0.00	2	3.64
CT only	0	0.00	1	7.14	1	1.82
Targeted therapy	1	2.44	0	0.00	1	1.82
Hormone	1	2.44	0	0.00	1	1.82
Intervention	12	29.27	3	21.43	15	27.27
Palliative care only	4	9.76	5	35.71	9	16.36
I+SUR.	1	2.44	0	0.00	1	1.82
I+Targeted therapy	8	19.51	2	14.29	10	18.18
Total	41	100.00	14	100.00	55	100.00

** SUR. = Surgery

RT = Radiation therapy

CT = Chemotherapy

I = Intervention

Hormone = Hormonal therapy

TYPE OF TREATMENT IN HEPATOMA CANCER (IN BMC ONLY)

Type of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR. only	5	16.13	0	0.00	5	13.51
RT only	1	3.23	0	0.00	1	2.70
Targeted therapy	1	3.23	0	0.00	1	2.70
Hormone	1	3.23	0	0.00	1	2.70
Intervention	12	38.71	3	50.00	15	40.54
Palliative care only	3	9.68	1	16.67	4	10.81
I+SUR.	1	3.23	0	0.00	1	2.70
I+Targeted therapy	7	22.58	2	33.33	9	24.32
Total	31	100.00	6	100.00	37	100.00


** SUR. = Surgery

RT = Radiation therapy

I = Intervention

Hormone = Hormonal therapy

FOLLOW UP STATUS



** AWD = *Alive with disease*

DWD = *Dead with disease*

Loss Follow up = *Not attended*


No Follow up = *Intend not to continue diagnosis or treatment at BMC*

PROSTATE GLAND CANCER PATHOLOGY ACCORDING OF PROSTATE GLAND CANCER

Tumor site		Number
C61.9	Prostate gland	91
Total		91

Pathology Report		Number
M8000/3	Malignant neoplasm	24
M8140/3	Adenocarcinoma, NOS	64
M8550/3	Acinar adenocarcinoma	3
Total		91

AGE




METHOD OF DIAGNOSIS (TREATMENT IN BMC)

Method of diagnosis	Number	Percent
Biochemical	0	0.00
Other	3	6.98
Cytology	0	0.00
Histology	40	93.02
Imaging	0	0.00
Total	43	100.00

** Other = Previously diagnosed as Prostate gland cancer from other Hospital but no document of Pathology

STAGING (TREATMENT IN BMC)



** Unspecified stage = Incomplete staging due to Patient is not enough

TYPE OF TREATMENT (IN BMC ONLY)

Type of treatment	Number	Percent
SUR. only	14	32.56
RT only	8	18.60
Brachytherapy	5	11.63
Hormone	6	13.95
Palliative care	1	2.33
SUR.+RT	3	6.98
SUR.+H	1	2.33
RT+H	4	9.30
Im.+RT	1	2.33
Total	43	100.00


** SUR. = Surgery

RT = Radiation therapy

H (Hormone) = Hormonal therapy

Im. = Immunotherapy

FOLLOW UP STATUS



** AWD = *Alive with disease*

AOD = *Alive without disease*



Loss Follow up = *Not attended*

No Follow up = *Intend not to continue diagnosis or treatment at BMC*


HEMATOLOGIC MALIGNANCIES 2009

DISTRIBUTION OF HEMATOLOGIC MALIGNANCIES BY ICD-10


Code	Disease	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
C81	Hodgkin's disease	8	11.27	5	14.29	13	12.26
C82	Follicular NHL	4	5.63	2	5.71	6	5.66
C83	Diffuse NHL	17	23.94	10	28.57	27	25.47
C84	Peripheral and cutaneous T-cell lymphoma	3	4.23	0	0.00	3	2.83
C85	Other and unspecified types of NHL	16	22.54	6	17.14	22	20.75
C90	Multiple myeloma	6	8.45	6	17.14	12	11.32
C91	Lymphoid leukemia	8	11.27	2	5.71	10	9.43
C92	Myeloid leukemia	9	12.68	4	11.43	13	12.26
Total		71	100.00	35	100.00	106	100.00



DISTRIBUTION OF HEMATOLOGIC MALIGNANCIES BY AGE & SEX




DISTRIBUTION OF HEMATOLOGIC MALIGNANCIES BY PATIENT CATEGORIES



** Dx = Diagnosis for cancer
 Rx = Treatment
 Here = Within Bangkok Hospital Medical Center
 Other = Outside Bangkok Hospital Medical Center

DISTRIBUTION OF HEMATOLOGIC MALIGNANCIES BY FOLLOW UP STATUS



** AWD = Alive with Disease


AOD = Alive without Disease (Remission)

DWD = Dead with Disease



Intend not to Follow up = Intend not to continue diagnosis or treatment at BMC

DISTRIBUTION OF HEMATOLOGIC MALIGNANCIES BY OVERALL NATIONALITY

Nationality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
International	40	56.34	15	42.86	55	51.89
Thai	31	43.66	20	57.14	51	48.11
Total	71	100.00	35	100.00	106	100.00




DISTRIBUTION OF LYMPHOMA BY AGE & SEX



DISTRIBUTION OF LYMPHOMA BY METHOD OF DIAGNOSIS

Conclude method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Histopathology only	15	75.00	5	55.56	20	68.97
Histo+Flow cytometry	2	10.00	2	22.22	4	13.79
Histo+Flow cyto+Chromosome	0	0.00	1	11.11	1	3.45
Histo+Immunohistochemistry	2	10.00	0	0.00	2	6.90
Histo+Immuno+Chromosome	0	0.00	1	11.11	1	3.45
Histo+Immuno+Flow cytometry	1	5.00	0	0.00	1	3.45
Total	20	100.00	9	100.00	29	100.00

DISTRIBUTION OF LYMPHOMA BY STAGING (TREATMENT AT BMC)



** Unstage = Incomplete staging due to Patient information is not enough


DISTRIBUTION OF LYMPHOMA BY TREATMENT (TREATMENT AT BMC)

Conclude Tx.	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
CT only	6	30.00	2	22.22	8	27.59
RT only	4	20.00	0	0.00	4	13.79
Supportive care	2	10.00	1	11.11	3	10.34
Chemo+HSCT	1	5.00	0	0.00	1	3.45
Chemo+RT+HSCT	0	0.00	1	11.11	1	3.45
Chemo+RT	0	0.00	1	11.11	1	3.45
Chemo+Targeted	2	10.00	2	22.22	4	13.79
Chemo+Targeted+RT	1	5.00	0	0.00	1	3.45
Follow up	1	5.00	1	11.11	2	6.90
Surgery only	1	5.00	0	0.00	1	3.45
Surgery+Chemo+Targeted	1	5.00	1	11.11	2	6.90
Surgery+Chemo+Targeted+RT	1	5.00	0	0.00	1	3.45
Total	20	100.00	9	100.00	29	100.00

** HSCT = Hematopoietic stem cell transplantation

CT = Chemotherapy

RT = Radiation therapy




MULTIPLE MYELOMA (C90)

DISTRIBUTION OF MULTIPLE MYELOMA BY AGE & SEX

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
30-34	1	16.67	0	0.00	1	8.33
35-39	0	0.00	1	16.67	1	8.33
40-44	0	0.00	0	0.00	0	0.00
45-49	0	0.00	0	0.00	0	0.00
50-54	0	0.00	1	16.67	1	8.33
55-59	1	16.67	2	33.33	3	25.00
60-64	2	33.33	0	0.00	2	16.67
65-69	1	16.67	1	16.67	2	16.67
70-74	0	0.00	1	16.67	1	8.33
75-79	1	16.67	0	0.00	1	8.33
Total	6	100.00	6	100.00	12	100.00

DISTRIBUTION OF MULTIPLE MYELOMA BY PATIENT NATIONALITY



DISTRIBUTION OF MULTIPLE MYELOMA BY METHOD OF DIAGNOSIS


Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Histopathology only	1	33.33	1	25.00	2	28.57
Histo+Flow cytometry	1	33.33	1	25.00	2	28.57
Histo+Flow cyto+Chromosome	0	0.00	2	50.00	2	28.57
Histo+Immunohistochemistry	1	33.33	0	0.00	1	14.29
Total	3	100.00	4	100.00	7	100.00

DISTRIBUTION OF MULTIPLE MYELOMA BY STAGING (TREATMENT AT BMC)

Stage	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	0	0.00	0	0.00	0	0.00
Stage II	0	0.00	0	0.00	0	0.00
Stage III	1	33.33	4	100.00	5	71.43
Unstage	2	66.67	0	0.00	2	28.57
Total	3	100.00	4	100.00	7	100.00



DISTRIBUTION OF MULTIPLE MYELOMA BY TREATMENT (TREATMENT AT BMC)




** HSCT = Hematopoietic stem cell transplantation

LEUKEMIA (C90 - C91)


DISTRIBUTION OF LEUKEMIA BY AGE & SEX

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00-04	1	5.88	1	16.67	2	8.70
05-09	1	5.88	1	16.67	2	8.70
10-14	0	0.00	0	0.00	0	0.00
15-19	1	5.88	0	0.00	1	4.35
20-24	0	0.00	0	0.00	0	0.00
25-29	0	0.00	0	0.00	0	0.00
30-34	0	0.00	0	0.00	0	0.00
35-39	0	0.00	1	16.67	1	4.35
40-44	2	11.76	0	0.00	2	8.70
45-49	1	5.88	1	16.67	2	8.70
50-54	2	11.76	0	0.00	2	8.70
55-59	4	23.53	0	0.00	4	17.39
60-64	1	5.88	2	33.33	3	13.04
65-69	1	5.88	0	0.00	1	4.35
70-74	0	0.00	0	0.00	0	0.00
75-79	2	11.76	0	0.00	2	8.70
80-84	1	5.88	0	0.00	1	4.35
Total	17	100.00	6	100.00	23	100.00



DISTRIBUTION OF LEUKEMIA BY AGE

Age	Number	Percent
<15 yr	5	21.74
≥15 yr	18	78.26
Total	23	100.00




DISTRIBUTION OF LEUKEMIA BY METHOD OF DIAGNOSIS

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Histopathology only	3	37.50	4	100.00	7	58.33
Histo+Flow cytometry	1	12.50	0	0.00	1	8.33
Histo+Flow cyto+Chromosome	4	50.00	0	0.00	4	33.33
Total	8	100.00	4	100.00	12	100.00

DISTRIBUTION OF LEUKEMIA BY TREATMENT (TREATMENT AT BMC)

Conclude Tx.	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Chemo only	3	37.50	1	25.00	4	33.33
Supportive care	4	50.00	1	25.00	5	41.67
Chemo+RT	1	12.50	0	0.00	1	8.33
Follow up	0	0.00	2	50.00	2	16.67
Total	8	100.00	4	100.00	12	100.00



AGE DISTRIBUTION IN ALL MALE CANCER NUMBER OF CASE

Age	Tumour/Site	Age Group																	Total	%			
		00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84			85-89	90-94	95+
C00	Lip	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0.14
C01-C02	Tongue	0	0	0	0	0	1	1	0	0	2	0	2	6	0	0	0	0	0	0	0	12	1.70
C03	Gum	0	0	0	0	0	0	0	0	0	0	1	0	2	0	1	0	0	0	0	0	4	0.57
C04	Floor of mouth	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0.14
C05	Palate	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	2	0.28
C06	Other part of mouth	0	0	0	0	0	0	0	0	0	1	0	1	0	1	0	0	1	0	0	0	4	0.57
C07	Parotid gland	0	0	0	0	0	0	0	0	0	1	0	0	2	0	0	0	1	0	0	0	5	0.71
C08	Salivary gland	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	3	0.43
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	4	0.57
C10	Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C11-C14	Head & neck	0	0	0	0	0	1	1	5	5	5	2	8	2	1	2	0	0	0	0	0	32	4.54
C15	Esophagus	0	0	0	0	0	0	0	0	1	3	4	2	3	2	3	2	0	0	0	0	20	2.84
C16	Stomach	0	0	0	0	1	0	1	1	3	2	3	4	3	4	3	0	1	0	0	0	20	2.84
C17	Small intestine	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	2	0.28
C18-C20	Colon & Rectum	0	0	0	0	0	2	3	4	4	9	10	14	20	12	9	6	0	2	0	104	14.75	
C21	Anus	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	2	0.28
C22-C24	Liver & Hepatobiliary	0	0	0	0	0	0	0	1	8	7	13	12	10	6	8	2	1	0	0	74	10.50	
C25	Pancreas	0	0	0	0	0	0	1	2	0	1	5	0	3	2	1	3	0	0	0	18	2.55	
C26	Other and ill-defined digestive organ	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0.14	
C30	Nasal cavity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C31	Accessory sinuses	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	2	0.28	
C32	Larynx	0	0	0	0	0	0	0	0	1	0	2	2	2	2	3	2	1	1	0	14	1.99	
C33-C34	Lung	0	0	0	0	0	0	2	1	2	6	9	19	24	11	21	15	8	1	0	119	16.88	
C37	Thymus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C38	Mediastinum	0	0	0	0	0	0	1	0	0	0	1	0	0	0	2	0	0	0	0	4	0.57	
C40-C41	Bone	0	0	0	1	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	3	0.43	

SUMMARY OF ALL CANCERS

Age	Tumor/Site	00-04																Total	%				
		00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79			80-84	85-89	90-94	95+
C43-C44	Skin	0	0	0	0	0	0	0	1	3	3	1	3	4	3	4	2	4	0	0	0	28	3.97
C48	Retroperitoneum	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0.28
C49	Connective tissue	1	0	1	0	0	0	1	4	1	1	0	2	0	0	1	0	1	0	0	0	12	1.70
C50	Breast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C51	Vulva	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C52	Vagina	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C53	Cervix	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C54	Corpus uteri	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C55	Uterus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C56	Ovary	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C57	Other female genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C60	Penis	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.14
C61	Prostate gland	0	0	0	0	0	0	0	0	2	6	12	14	17	19	10	7	4	0	0	0	91	12.91
C62	Testis	0	0	0	0	1	2	0	2	1	0	0	0	0	0	0	0	0	0	0	0	6	0.85
C63	Scrotum, skin	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0.14
C64-C65	Urinary tract	1	0	0	1	0	0	0	2	2	2	4	2	5	1	3	0	1	0	2	0	26	3.69
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0.14
C67	Bladder	0	0	0	0	0	1	0	0	0	5	7	8	7	4	6	2	0	0	0	0	45	6.38
C68	Urinary organ unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C69	Eye & adnexa	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C70-C71	Brain	1	1	0	1	1	0	1	2	0	0	1	0	3	1	0	0	0	0	0	0	12	1.70
C72	Spinal cord & CNS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C73	Thyroid gland	0	0	0	1	1	1	2	0	3	2	3	2	2	2	0	0	0	0	0	0	19	2.70
C74	Adrenal gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C75	Other & endocrine gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C76	Other & ill-defined	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C80	Unknown primarysite	0	0	0	0	1	0	0	0	1	0	1	2	2	1	0	1	0	1	0	0	10	1.42
Total		3	1	2	1	5	6	14	17	35	48	71	92	119	85	90	60	41	12	2	2	705	100.00

SUMMARY OF ALL CANCERS

Age	Tumor/Site	00 - 04																		Total	%		
		00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89			90-94	95+
C43-C44	Skin	0	0	1	0	0	0	1	1	0	3	0	1	0	1	1	1	0	2	0	0	12	1.74
C48	Retroperitoneum	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C49	Connective tissue	0	0	0	1	0	0	0	0	2	1	0	0	0	0	0	0	0	0	0	0	4	0.58
C50	Breast	0	0	0	0	2	10	18	30	48	40	42	27	20	5	8	7	2	2	0	1	260	37.68
C51	Vulva	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0.14
C52	Vagina	0	0	0	0	0	0	1	0	0	0	1	0	0	2	0	0	0	0	0	0	4	0.58
C53	Cervix	0	0	0	0	0	3	5	6	7	9	5	7	3	1	4	2	0	0	0	0	52	7.54
C54	Corpus uteri	0	0	0	0	0	0	1	2	1	4	2	4	2	1	1	3	1	2	0	0	24	3.48
C55	Uterus	0	0	0	0	0	0	0	0	1	0	0	2	0	0	0	0	0	0	0	0	3	0.43
C56	Ovary	0	0	0	0	0	2	2	6	5	4	6	1	3	3	1	2	0	0	0	0	35	5.07
C57	Other female genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C60	Penis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C61	Prostate gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C64-C65	Urinary tract	0	0	0	0	0	0	0	0	5	0	2	0	3	2	2	0	0	0	1	0	15	2.17
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C67	Bladder	0	0	0	0	0	0	0	1	0	0	1	1	2	2	2	0	0	0	0	0	9	1.30
C68	Urinary organ unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C69	Eye & adnexa	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C70-C71	Brain	0	2	1	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	5	0.72
C72	Spinal cord & CNS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C73	Thyroid gland	0	0	0	2	2	5	4	8	1	1	4	1	1	2	0	0	1	0	0	0	32	4.64
C74	Adrenal gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C75	Other & endocrine gland	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0.14
C76	Other & ill-defined	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C80	Unknown primarysite	0	0	0	0	0	0	0	1	1	1	2	1	2	0	1	0	1	0	0	0	10	1.45
D05	Ductal carcinoma in situ of breast	0	0	0	0	0	3	1	6	7	2	1	3	2	0	1	0	0	0	0	0	26	3.77
Total		0	2	2	1	5	8	25	42	77	95	78	93	79	64	35	39	25	13	4	3	690	100.00


Hematologic Malignancies 2009 : Executive Summary

A large number of patients who suffered from hematologic malignancies, accompanied with their family members, have come to Wattanosoth Cancer Hospital in order to be assessed for the proper diagnoses, to get appropriate and optimal treatment, or to seek advice or second opinion. There were totally 106 hematologic malignant patients registered in our tumor registry during the year 2009. Gender proportion of the patients, male to female was about 2:1 (71:35). Approximately 48 percent of patients were Thais (51 patients), while the remaining were international visitors (55 patients) coming from several countries, such as UAE, Oman, Qatar, Ethiopia, Bangladesh, India, Myanmar, The Philippines, etc. Various types of hematologic malignancy included non-Hodgkin lymphoma (NHL), Hodgkin disease, leukemia, and multiple myeloma. NHL was the most common among these malignant diseases. The numbers of patients diagnosed as NHL, leukemia, Hodgkin disease, and multiple myeloma were 58, 23, 13, and 12, respectively. The detailed distribution of each disease is shown in table 1.


Overall there were 7 pediatric patients (7 percent), aged less than 15 years old, but the majorities were 99 adult patients (93 percent), aged over 15. The patient age ranged from the first year of life to the age up to 89 years, where as the most common age group for all hematologic malignant diseases was range between 40 to 64 years. The most common age group for malignant lymphoma ranged between 35 to 64 years. The most common age group for leukemia ranged between 35 to 69 years. In leukemia group there were 5 pediatric patients (22 percent) under the age of 15 years and 18 adult patients (78 percent). The common age group for multiple myeloma ranged between 50 to 79 years.

At Wattanosoth Cancer Hospital there are various kinds of modern treatment modalities, including chemotherapy, radiotherapy, targeted therapy, surgery, supportive therapy, and the sophisticated hematopoietic stem cell transplantation (either autologous or allogeneic). In some condition each of these modalities may be combined for the patient. There were about half of registered patients continuing treatment here after they were initially evaluated for certain diagnoses and staging. Some patients, in particular foreign visitors, achieved certain diagnoses elsewhere then were referred to get appropriate and standard treatment here. Overall in the group of patients receiving treatment and still following-up the survival rate was about 85%.

Analysed in September, 2010.



กิจกรรม Activity



SHA Conference & Contest

ไปสมัคร Tumor Registry Program นำเสนอในงาน SHA Conference & Contest ระหว่างวันที่ 10-11 พฤศจิกายน 52 ณ โรงแรมอิมพีเรียล คีนส์ พาร์ค



โรงพยาบาลพระมงกุฎเกล้าฯ

คณะแพทย์ และเจ้าหน้าที่จากโรงพยาบาลพระมงกุฎเกล้าฯ ได้เข้าเยี่ยมชมการดำเนินงานเกี่ยวกับระบบทะเบียนมะเร็งของโรงพยาบาลวชิรเมดิคอล เมื่อวันที่ 16 กุมภาพันธ์ 2553 โดยมีรองศาสตราจารย์นายแพทย์ คมกฤษ ฐานิสโร และทีมงานให้การต้อนรับ และบรรยายสรุป

กิจกรรม Activity



โรงพยาบาลกรุงเทพ รวยอง

วันที่ 22-26 มีนาคม 2553 โรงพยาบาลกรุงเทพ รวยอง ได้ทำการจัดตั้งระบบทะเบียนมะเร็ง โดยเจ้าหน้าที่ทะเบียนมะเร็งจากโรงพยาบาลวชิรโลก เป็นผู้อบรมให้ทราบถึงโครงสร้าง และหลักการเกี่ยวกับระบบทะเบียนมะเร็ง ลำดับขั้นตอนในการจัดทำทะเบียนมะเร็ง รวมถึงการรายงานข้อมูล และการนำข้อมูลไปใช้



โรงพยาบาลสมิติเวช สุขุมวิท


วันที่ 30 มีนาคม 2553 รองศาสตราจารย์นายแพทย์ คมกฤษ ฐาภิโร ได้อบรมเรื่อง “ทะเบียนมะเร็ง” เบื้องต้น แก่เจ้าหน้าที่ และพยาบาล โรงพยาบาลสมิติเวช สุขุมวิท



โรงพยาบาลกรุงเทพ พญา

เจ้าหน้าที่จากโรงพยาบาลกรุงเทพ พญา ได้เข้าเยี่ยมชมการดำเนินงานเกี่ยวกับระบบทะเบียนมะเร็งของโรงพยาบาลวชิรโลก เมื่อวันที่ 15 มิถุนายน 2553 โดยมีทีมงานทะเบียนมะเร็งให้การต้อนรับ และบรรยายสรุป

Highlighted Technology




C-11 acetate PET-CT

C-11 acetate is a metabolic substance of the oxidation and precursors of amino acid and sterol. It has proven to be useful in detecting many kinds of malignancy such as nasopharyngeal cancer, well differentiated hepatocellular carcinoma, pancreatic cancer and prostate cancer, etc. Studies of using C-11 acetate for detecting well differentiated hepatoma and prostate cancer are reported. It is known that both of them are non FDG avid tumors. Dual isotope, FDG and C11 acetate, PET scan seem to be useful for evaluation of hepatocellular carcinoma with high accuracy.



Bone Marrow Transplantation

Here is the picture showing the patient, 3-year-old boy, with his family and sister who was his bone marrow donor, together with the doctor and nurse. Happiness could be felt as expression in everyone's eyes. He was previously suffered from beta-thalassemia disease. Now he is successfully cured by methods of bone marrow transplantation performed at Bangkok Blood and Marrow Stem Cell Transplantation Unit in Wattanosoth Cancer Hospital. Not only thalassemia and marrow defective diseases but also many types of hematologic malignancies, such as leukemia, lymphoma, myeloma, can be treated by bone marrow or hematopoietic stem cell transplantation.



Radiofrequency Ablation

RFA (radiofrequency ablation)

Trend in oncology treatment has been changed to less invasive and use less big operation; liver cancer for example. Radiofrequency ablation treatment is the way we insert the medium-sized needle probe into the target organ and deliver heat energy to destroy the cancer under controlled monitoring and imaging guidance. This means we can kill cancer through the tiny scar on the skin, accurate targeting and very safe or lesser complication. This highlighted technology is worldwidely accepted and used in not just liver cancer but included the lung, kidney, bone cancer.



VMAT

VMAT (Volumetric Modulated Arc Therapy) is a significant improvement to existing advanced radiation therapy techniques, often referred to as IMRT (Intensity Modulated Radiation Therapy) and offers a faster alternative to helical tomotherapy. The target continuously is irradiated while the source of the beam is rotated around the patient in single or multiple arcs. By simultaneously controlling gantry position, gantry speed, leaves of the multi-leaf collimator (MLC), collimator angle and dose rate, a highly conformal dose distribution is created in significantly less time than with today's techniques. A treatment session typically can be conducted in five minutes or less, including true 3D imaging to secure the location of the target.



โรงพยาบาลกรุงเทพ
BANGKOK HOSPITAL

2 Soi Soonvijai 7, New Petchburi Rd., Bangkok 10310

Tel. 0-2310-3000 Fax 0-2318-1546

www.bangkokhospital.com, www.wattanosoth.com